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Abstract
Aims: To discuss the terminology to define and classify actinic cheilitis (AC) and to 
build a consensus on the diagnostic and therapeutic approaches to AC.
Methods: Two- round Delphi study using a questionnaire including 34 closed sen-
tences (9 on terminology and taxonomy, 5 on potential for malignant transformation, 
12 on diagnostic aspects, 8 on treatment) and 8 open questions. Experts’ agreement 
was rated using a Likert scale (1– 7).
Results: A consensus was reached on 24 out 34 statements (73.5%) and on 5 out of 8 
(62.5%) close- ended questions. The response rate was identical in both rounds (attri-
tion of 0%). AC is the term with the highest agreement (median of 7 (strongly agree; 
IQR: 6– 7)) and the lowest dispersion (VC = 21.33). ‘Potentially malignant disorder’ 
was the preferred classification group for AC (median of 7) and 85.6% of participants 
showing some level of agreement (CV < 50). Experts (66.75%) consider AC a clini-
cal term (median: 7; IQR: 4– 7) and believe definitive diagnosis can be made clinically 
(median: 6; IQR: 5– 7), particularly by inspection and palpation (median: 5; IQR: 4– 6). 
Histopathological confirmation is mandatory for the management of AC (median: 5; 
IQR: 2.5– 7), even for homogeneous lesions (median: 5; IQR: 3.5– 6). Consensus was 
reached on all treatment statements (VC < 50).
Conclusions: AC is a potentially malignant disorder with a significant lack of agree-
ment on diagnostic criteria, procedures, biopsy indications and the importance of 
techniques to assist in biopsy. A consensus was reached on nomenclature and man-
agement of this disorder.
K E Y W O R D S
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1  |  INTRODUC TION
The term actinic cheilitis (AC) in scientific literature describes 
changes induced by chronic exposure to sunlight (ultraviolet A 
wavelength 320– 400 nm and largely ultraviolet B wavelength 290– 
320 nm) mostly affecting the lower lip.1 However, AC is considered 
a misnomer by some authors who use alternative terms, like solar 
cheilitis,2 solar cheilosis,3 solar keratosis4 or actinic keratosis of the 
lip.5 This terminological controversy is based on the understanding 
of the pathobiology of the condition as primarily inflammatory1 or 
non- inflammatory2 and on the appellation (actinic: ‘a ray’ vs. solar) of 
the aetiologic radiation.2- 5
There is also a lack of consensus on the nature of AC as either 
a ‘precancerous or potentially malignant’6,7 or a primarily neoplas-
tic (intra- epithelial neoplasia) condition,3,8- 10 which may explain the 
divergences in case definition, diagnostic criteria and management. 
Additionally, existing literature shows a disagreement on whether 
AC should be used as a clinical term where biopsy is not always 
recommended11 or used a preliminary clinical diagnosis for which 
histopathological examination is mandatory to reach a definitive di-
agnosis.3 Even the requirement of epithelial dysplasia of the lip epi-
thelium to diagnose AC is a matter of debate.12,13
These uncertainties may well explain the wide differences in re-
ported AC prevalence when estimated in terms of histopathological 
(2.08%; 95%CI: 0.94– 3.67)11 or clinical (31.3%; 95%CI: 30.5– 35.7) 
criteria14 and highlight the need for a consensus on an unequivocal 
definition of AC.
A range of medical and surgical procedures (5% topical 5- FU, 
5% topical imiquimod, 3% diclofenac gel, chemical peels, dermabra-
sion, photodynamic therapy, cryotherapy, electrosurgery, Er:YAG 
laser and vermilionectomy (cold blade and CO2 laser), together with 
Mohs micrographic surgery) have been used for treating AC.3,15- 18 
However, and despite the superiority of surgery compared with 
medical therapies (92.8% vs. 65.9% showing remission with lower 
recurrence rates (8.4% vs. 19.2%)16), there is no consensus on the 
optimal strategy for treatment of AC16- 18 because both approaches 
have benefits and drawbacks.19
Thus, the current comprehension regarding AC clearly requires 
an effort to minimize disparities and reach agreements on termino-
logical and taxonomical aspects, as well as in its diagnosis and treat-
ment. In this vein, an expert consensus (Delphi method) approach 
can support clinical decision- making, particularly when evidence 
about a given topic is contradictory.20 The Delphi method is aimed 
at structuring a consensus and it is based upon the anonymity of the 
experts among themselves and on the iteration with controlled feed-
back (experts are consulted more than once).21- 26 This technique is a 
procedure for group communication meant to reach a convergence 
of opinion on a specific ‘real- world’ issue.26
The objectives of this investigation were i) to discuss and agree 
upon the most appropriate terminology to define and classify AC 
and ii) to build a consensus about the diagnostic and therapeutic ap-
proaches to AC.
2  |  MATERIAL S AND METHODS
A two- round Delphi was designed according to the guidance on con-
ducting and reporting Delphi studies.21 A steering committee was 
established, and 21 experts (9 dermatologists, 9 specialists in Oral 
Medicine, and 3 oral pathologists) were recruited from a consortium 
of 11 academics and 10 clinical specialists across Europe and Latin 
America. Experts were selected through a bibliographical search 
(contributing at least one publication on this topic) and from their 
clinical experience (>15 years).
Our previous systematic review15 permitted the identification 
of terminological and taxonomical inconsistencies, along with dis-
cordances in diagnostic and therapeutic criteria for AC. As a result, 
a questionnaire was built including 34 closed sentences (9 on ter-
minology and taxonomy, 5 on potential for malignant transforma-
tion, 12 dealing with diagnostic aspects, as well as 8 statements on 
AC treatment) together with 8 open questions. The instrument was 
electronically circulated to the panel.
The first round (R1: March 2020) used a Likert scale (1 to 7; 1: 
strongly disagree – 7: strongly agree) to assess the level of con-
cordance with the closed sentences presented to the experts.26 
Participants were also asked to cast their degree of confidence on 
their responses using another Likert scale (1: very uncertain – 7: very 
certain). Once the obtained information was analysed and synthe-
sized, and considering the feedback from the panel, the open ques-
tions in the instrument were changed into close- ended ones and the 
second round (R2: June 2020) was initiated. In addition to the sec-
ond questionnaire, the experts received information about the over-
all response of the group in R1. In case a participant disagreed in one 
or more of his/her responses with the panel (agree/strongly agree 
or disagree/strongly disagree), and to favour consensus, the person 
was asked to reconsider the score allocated to his/her R1 respon-
se(s). This permitted the expert to bring his/her responses closer to 
the group's opinion or to remain with his/her previous response and 
to justify his/her score.
For purposes of this study, a consensus for close- ended ques-
tions was defined as ≥75% agreement by the experts. With reference 
to the sentences, a <50 variation coefficient (minor variability among 
experts) was considered an indicator for agreement. The criterion 
for dropping items at R1 was pre- established considering a minimum 
acceptable level of confidence in expressing an opinion (≥ 5).
This study was approved by the University of Santiago de 
Compostela Research Ethics Committee (#USC- 17/2020). A decla-
ration of interests was completed by all participants.
2.1  |  Statistical analysis
A quantitative analysis of the results of both R1 and R2 was un-
dertaken using the SPSS v.24 statistical package (SPSS Inc). The 
descriptive study used the median as a central trend indicator and 
the interquartile range as a measure of spread. The variability of the 
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experts’ scores (dispersion) for a given item was calculated using 
the coefficient of variation (standard deviation/mean). The level of 
agreement (percentage) was also described for close- ended ques-
tions. The opinions of the experts were also considered for non- 
consensual questions.
3  |  RESULTS
Twenty five experts were invited, and 21 agreed to participate in the 
study, resulting a recruitment rate of 84%.
The Delphi technique permitted a consensus on 24 out 34 state-
ments (73.5%) and on 5 out of 8 (62.5%) close- ended questions. The 
response rate was identical in both rounds, with an attrition of 0%, 
and just one statement was dropped because of a low level of con-
fidence among the participants in their responses. Results are dis-
played in Tables 1 to 4.
3.1  |  Nomenclature and taxonomy
Actinic cheilitis (AC) is the term with the highest level of con-
sensus among the experts, the lowest dispersion of scores 
(VC = 21.33) and a median of 7 (strongly agree) (IQR: 6– 7). No 
differences (p > 0.05) were observed between dermatologists 
and oral medicine specialists in terms of degree of agreement. 
Conversely, ‘solar cheilosis’ gathered the strongest disagree-
ment, with 85.7% of experts showing some level of discrepancy 
and a median of 1 (strongly disagree) (IQR: 1– 3). Actinic cheilo-
sis and solar cheilitis have also been discarded as inappropriate 
terms (CV >50).
Regarding taxonomy, ‘potentially malignant disorder’ was the 
most favoured by the group for classifying this entity, with a me-
dian of 7 and 85.6% of participants showing some level of agree-
ment (CV < 50). Other options, such as ‘precancerous lip lesion’, 
‘precursor lesion’ or ‘preinvasive malignant lesion’ have demonstrated 
lack of agreement (CV > 50) (Table 1). However, 23.8% of experts 
considered AC a primarily malignant lesion, and no significant dif-
ferences were identified between specialists regarding the degree 
of agreement about whether AC should be considered a preinvasive 
malignant lesion (p > 0.05). Furthermore, the panel exhibited their 
agreement with the statement that histopathological findings are 
not sufficient to predict a malignant transformation (median 6; IQR: 
4– 6) and also with the absence of methodologically sound prospec-
tive studies reporting on malignant transformations of AC (median: 
7; IQR: 5– 7) (Table 1).
TA B L E  1  Level of agreement (1– 3: Disagreement; 5– 7: Agreement) about nomenclature, taxonomy and potential for malignant 
transformation of actinic cheilitis in both rounds














Actinic cheilitis (- ) 90.4 7 (6– 7) 18.78 95.2 7 (6– 7) 21.33
Actinic cheilosis 57.1 (- ) 3 (1– 5) 68.96 66.6 (- ) 2 (1– 4) 72.85
Solar cheilitis 52.4 (- ) 3 (1– 4) 56.42 57.1 (- ) 3 (1.5– 4) 50.80
Solar cheilosis 66.7 (- ) 2 (1– 4) 73.15 85.7 (- ) 1 (1– 3) 63.00
Taxonomy
Preinvasive malignant lesion 81.0 (- ) 2 (1– 3) 61.94 71.4 (- ) 2 (1– 4.5) 67.3
Precancerous lip lesion 57.1 (- ) 4 (1.5– 6.5) 61.53 52.4 (- ) 4 (1.5– 6) 58.00
Potentially malignant disorder (- ) 71.5 6 (3– 7) 40.07 (- ) 85.6 7 (5.5– 7) 34.31
Potentially malignant lesion (- ) 70.0 6 (3– 7) 45.45 (- ) 66.7 6 (3– 7) 45.51
Precursor lesion 52.4 (- ) 2 (1– 4.5) 67.14 90.5 (- ) 3 (1– 3) 56.22
AC potential for malignant transformation
AC, good clinicopathological correspondence 60.0 (- ) 4 (3– 6) 36.97 57.2 (- ) 4 (4– 6) 28.88
AC, has a moderate rate (3%) of malignant 
transformation
(- ) 47.7 4 (3– 7) 45.07 (- ) 47.6 4 (3.5– 
6.5)
41.84
AC, there are no prospective studies reporting 
malignant transformation
(- ) 75.0 6 (5– 7) 29.38 (- ) 80.9 7 (5– 7) 27.25
Pathological findings are not sufficient to 
predict malignant transformation
(- ) 61.9 5 (4– 6) 34.08 (- ) 66.7 6 (4– 6) 32.72
Lip cancer can develop on non- dysplastic lip 
epithelia
(- ) 80.9 6 (5– 6.5) 26.38 (- ) 90.5 6 (5– 7) 21.87
Abbreviations: IQR, interquartile rage; VC, variation coefficient.
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From a clinical standpoint, the presence of erosions or ulcer-
ations, white patches and heterogeneous lesions was considered the 
best clinical predictors for malignant transformation in AC (76.9%). 
In addition, the presence of crusts, hyperkeratotic lesions, paleness 
and blurring of vermillion border can also indicate clinical suspicion 
for malignant transformation (80.95%) (Table 1).
3.2  |  Diagnosis of actinic cheilitis
Most experts (66.75%) consider AC a clinical term, not a histopatho-
logical description (median: 7; IQR: 4– 7), and believe a definitive 
diagnosis can be made solely by clinical criteria (median: 6; IQR: 5– 
7), particularly by inspection and palpation (median: 5; IQR: 4– 6). 
However, they find histopathological confirmation mandatory for 
the management of AC (median: 5; IQR: 2.5– 7), even for homogene-
ous lesions (median: 5; IQR: 3.5– 6).
An incisional biopsy of AC should be performed when a clinical di-
agnosis is established and when clinical changes or signs of suspicion 
for malignant transformation are detected during follow- up (95.23%). 
In this vein, an adequate histopathological diagnosis may be critical for 
selecting therapeutic approaches (median: 6; IQR: 3.5– 7). However, 
the maximum diagnostic certainty for AC is achieved by surgical exci-
sion (vermilionectomy) after incisional biopsy (ie by histopathological 
al assessment of the whole specimen) (median: 7; IQR: 6.5– 7).
Moreover, the experts consider solar elastosis as a pathogno-
monic microscopic finding in AC (median: 7; IQR: 5– 7), but no con-
sensus was reached about the requirement of epithelial dysplasia for 
a histopathological diagnosis of AC (median: 3; IQR: 1– 4; VC: 72.75; 
Table 2), with dermatologists consistently assigning significantly 
higher scores in favour of this diagnostic criterion as a requirement 
(p = 0.019).
3.3  |  Therapeutic approaches
Consensus was reached on all eight statements related to the treat-
ment of AC (VC < 50). According to the panel, treatment should be 
started once the diagnosis is established (including preventive meas-
ures) (80.95%), and thereafter, follow- up should include clinical visits 
every 3 or 6 months, depending on the clinical presentation and on 
the severity of the epithelial dysplasia (85.71%), Tables 3,4.
TA B L E  2  Level of agreement (1– 3: Disagreement; 5– 7: Agreement) on diagnostic aspects of actinic cheilitis in both rounds
Diagnostic features of actinic cheilitis













AC is clinical term, not a pathological one (- ) 56.6 7 (3.5– 7) 38.39 66– 70 7 (4– 7) 38.92
AC displays a wide histological variation, but it always 
includes some degree epithelial dysplasia
52.4 (- ) 3 (1– 6) 67.54 (- ) 61.30 3 (1– 4) 72.75
Solar elastosis is a constant histological finding in 
actinic cheilitis
(- ) 85.7 7 (5.5– 7) 28.81 (- ) 85.7 7 (5– 7) 22.83
AC can be diagnosed without any observable 
pathological alteration in the lip epithelium
61.9 (- ) 2 (1.5– 
5.5)
64.08 61.9 (- ) 3 (1.5– 
5.5)
62.53
A definitive diagnosis of AC can be established with 
clinical criteria alone
(- ) 71.4 6 (4– 6.5) 41.40 (- ) 80.9 6 (5– 7) 37.36
Histological confirmation is mandatory for a definitive 
diagnosis of AC
(- ) 57.1 5 (2.5– 7) 44.48 (- ) 52.4 5 (2.5– 7) 45.41
Biopsy is also indicated in AC homogeneous lesion (- ) 55.0 5 (3– 6) 39.09 (- ) 61.9 5 (3.5– 6) 35.08
Pre- treatment biopsy is not required when 
vermilionectomy is intended
66.7 (- ) 2 (1– 6) 76.00 71.4 (- ) 2 (1– 6) 79.29
How important are tissue autofluorescence 
procedures as assistant to biopsy
65.0 (- ) 2.5 
(1– 4)
53.58 85.7 (- ) 2 (1– 3) 48.85
AC Diagnosis (Certainty)
Certainty 1 (C1): Inspection and palpation permit a 
definitive clinical diagnosis
(- ) 57.1 5 (4– 6) 30.47 (- ) 61.8 5 (4– 6) 21.61
Certainty 2 (C2): Clinical diagnosis supplemented 
by pre- treatment Incisional biopsy permits a 
definitive clinical- pathological diagnosis
(- ) 95.2 7 (6– 7) 11.34 (- ) 100 7 (6– 7) 6.85
Certainty 3 (C3): Surgical excision after incisional 
biopsy (Pathological assessment of whole 
specimen) permits a definitive diagnosis with 
maximum level of certainty
(- ) 90.5 7 (7– 7) 16.28 (- ) 90.5 7 (6.5– 7) 15.87
Abbreviations: IQR, interquartile range; VC, variation coefficient.
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In mild AC cases, once clinical diagnosis is established, treat-
ment could start without awaiting histopathological confirmation 
(median: 5; IQR: 2.5– 7). Dermatologists elicited a higher level of 
agreement with this approach than did experts in Oral Medicine 
and Pathology (p = 0.014). Particularly, non- dysplastic AC lesions 
could be treated by non- surgical approaches (drugs and/or photo-
dynamic therapy) (median: 6; IQR: 5– 6), which offer good cosmetic 
outcomes after treatment and minor adverse events (median: 6; 
TA B L E  3  Level of agreement (1– 3: Disagreement; 5– 7: Agreement) on approaches for treating actinic cheilitis in both rounds
Therapeutic approaches



















An adequate histological diagnosis may be critical for 
selecting therapeutic approach
(- ) 71.4 6 (4– 7) 35.98 (- ) 66.7 6 (3.5– 7) 33.52
For mild AC cases, treatment can be started after 
clinical diagnosis without pathological confirmation
(- ) 66.6 6 (3– 7) 42.8 (- ) 71.4 5 (2.5– 7) 39.30
Non- dysplastic AC lesions— either circumscribed 
or diffuse— may be treated using drugs and/ or 
photodynamic therapy
(- ) 85.0 6 (5– 6) 26.54 (- ) 85.7 6 (5– 6) 23.79
Non- surgical treatments offer clear advantages (good 
cosmetic outcomes, low cost, and minor adverse 
events)
(- ) 61.90 5 (3.5– 6) 35.71 (- ) 80.9 6 (4– 6) 31.35
Surgical approaches are better than non- surgical ones 
for removing AC with moderate/severe dysplasia
(- ) 85.0 7 (5– 7) 26.77 (- ) 85.3 7 (5– 7) 26.21
Non- surgical treatments result in a higher rate of 
recurrences than surgical ones.
(- ) 66.7 6 (4– 6) 22.87 (- ) 76.2 6 (4.5– 
6.5)
19.78
Vermilionectomy techniques may be reserved for 
diffuse AC with severe dysplasia
(- ) 95.2 6 (6– 7) 13.46 (- ) 95.2 6 (6– 7) 13.84
Laser vaporization techniques may be used in diffuse or 
multicentric lesion with mild dysplasia (When high 
diagnostic certainty is achieved)
(- ) 66.6 6 (3.5– 7) 40.46 (- ) 71.5 6 (4– 7) 35.87
Abbreviations: IQR, interquartile range; VC, variation coefficient.








1- Actinic cheilitis is a primarily malignant lesion 5 (23.80) 12 (57.14) 4 (19.04)
2- Clinical diagnosis of actinic cheilitis should be supplemented with information about the 
degree of dysplasia (if any), or about the presence of lip carcinoma.
13 (61.90) 2 (9.52) 6 (28.57)
3- Assessing p53 expression together with clinic- pathological findings may contribute to 
predict the risk for malignant transformation.
8 (38.09) 7 (33.33) 6 (28.57)
4- The presence of erosions or ulcerations, white patches and heterogeneous lesions are the 
best clinical predictors for malignant transformation in actinic cheilitis.
16 (76.19) 2 (9.25) 3 (14.28)
5- The presence of crusts, hyperkeratotic lesions, paleness and blurring of the vermillion border 
can also indicate a clinical suspicion for malignant transformation.
17 (80.95) 2 (9.52) 2 (9.52)
6- About when to undertake an incisional biopsy in AC: It should be taken when a clinical 
diagnosis is established and also when clinical changes or signs of suspicion for malignant 
transformation are detected during follow- up.
20 (95.23) (- ) 1 (4.76)
7- In my experience, the follow- up protocol for AC should include control visits every 3 or 
6 months depending on the clinical presentation and on the severity of the dysplasia.
18 (85.71) 1 (4.76) 2 (9.52)
8- Treatment for AC should be stated when the diagnosis is established (preventive measures, 
etc…)
17 (80.95) (- ) 4 (19.04)
9- Follow- up visits after treatment: The first visits should be adapted to the severity of the 
lesion and the type of treatment. Later, they should be scheduled every 3 or 6 months 
depending on clinicopathological criteria and on the response to treatment.
19 (90.47) 1 (4.76) 1 (4.76)
Abbreviation: N.A, no answers.
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IQR: 4– 6), but higher recurrence could be expected (median: 6; 
IQR: 4.5– 6.5).
Surgical approaches are better than non- surgical ones, and laser 
vaporization techniques could be used for multicentric or diffuse AC 
lesions with mild epithelial dysplasia (median: 6; IQR: 4– 7). Besides, 
AC lesions with moderate/severe epithelial dysplasia (median: 6; 
IQR: 5– 7), and particularly those with diffuse presentations and with 
severe epithelial dysplasia are best treated by vermilionectomy tech-
niques to prevent the development of a carcinoma (median: 6; IQR: 
6– 7), Table 3.
4  |  DISCUSSION
4.1  |  Strengths and limitations of the study
The Delphi methodology was used to address consensus with the 
objective of contributing to a common effort targeted towards 
agreement.27 A standardized Delphi procedure21,24 was used on a 
non- homogeneous consensus group to minimize the impact of in-
dividual opinions.22,27 Considering the composition of the panel in-
fluences the rating of Delphi studies,27 we have used strict criteria 
for the recruitment of the 21 experts (6 of them are university full 
professors). In addition, this methodology permits the identification 
of any different opinions between specialties.27
In an attempt to evaluate the agreement level of the answers, 
a seven- point scale was adopted to be more discriminative,22,25 to-
gether with the selection of quality indicators for the study (num-
ber of rounds, reproducible criteria for the selection of experts and 
criteria for dropping items). Furthermore, the degree of confidence 
with each of the answers was incorporated as a subrogated indi-
cator for the quality of the data obtained.22,25 However, reaching 
a consensus does not indicate the results of the consensus being 
factual,27 and it does not substitute for established clinical guide-
lines based on strong scientific evidence. Unfortunately, existing ev-
idence on diagnosis and treatment of AC is scarce and disconcordant 
and a guideline development by professional societies may be very 
useful supporting future clinical practice.
4.2  |  Taxonomy and potential for malignant 
transformation
Although ‘solar cheilosis’ has been recommended as an appropriate 
term for labelling this entity (inflammation is not the starting event, 
and ‘solar’ is more accurate than ‘actinic’, that includes other types 
of radiation as aetiological agent3), ‘actinic cheilitis’ is the most fre-
quently term used in the literature13 and the best valued by the 
panel of experts.
Classically, the terms ‘potentially malignant’, ‘premalignant’ and 
‘precancerous’ have been used interchangeably,7,18 although ‘poten-
tially malignant disorder’ has been the term adopted by the WHO 
Collaborating Centre in 2007.28,29 This concept combines both 
precancerous lesions and conditions separately grouped in the ear-
lier WHO definitions.30 Potentially, malignant is more suited as not 
all ACs will eventually develop into lip cancer.6,29,30 This nomencla-
ture has reached the highest level of consensus in the current study, 
although some authors9,10 still consider AC as micro- invasive, super-
ficial, incipient malignant epithelial neoplasia.
The chances for a patient with actinic changes and lip carci-
noma to develop a second primary lip cancer are 2.5 times higher 
than for a patient without AC.2 In addition, 95% of squamous 
cell carcinomas of the lip occur on a background of AC.14,31,32 
Conversely, and considering that more than two decades of 
chronic sun exposure is needed for AC to turn into lip cancer2 and 
with the limited long- term, prospective, observational studies on 
non- treated AC, it is difficult to know the actual rate of malignant 
transformation of this entity.31 It is not surprising that the mod-
erate rate of malignant transformation, 3%, reported in a recent 
systematic review31 supported by a single study33 has not reached 
a consensus of experts.
AC may present a wide range of clinical features which do not 
unveil the severity of the lesion.9,32 Thus, the presence of ulceration, 
severe inflammation, blurring of the vermilion, nodularity, atrophy, 
friability and chronic bleeding is indicative of epithelial dysplasia 
or presence of malignization.3,34 Besides, the panel has agreed the 
presence of hyperkeratotic lesions, paleness and heterogeneous le-
sions as additional clinical predictors for malignant transformation. 
Although histopathological changes are not sufficient for predict-
ing the risk for malignant transformation of AC29 because malignant 
transformation can also occur in non- dysplastic epithelia,24 epithe-
lial dysplasia becomes relevant with AC progression.35 In addition, 
different biomarkers (including overexpression of p53) have proved 
able to identify early events in lip carcinogenesis but the precise 
contribution of biomarkers to clinical practice is very limited.35,36
4.3  |  Diagnosis of actinic cheilitis
Considering AC being a clinical term6 and obtaining a biopsy would 
be particularly recommended from clinically suspicious sites,12,37 cli-
nicians should avoid treating AC relying on clinical findings alone.3 
Considering the divergence between the clinical appearance of the 
lesion and its histopathological characteristics, combined with the 
difficulties for a single biopsy to represent the whole lesion, the use 
of multiple incisional biopsies38 or other procedures to enhance di-
agnostic accuracy39 would be desirable. Autofluorescence imaging 
and staining with toluidine blue combined with clinical examina-
tion may well be one of the adjunctive chair- side procedures39 for 
detecting high- risk zones and selecting a biopsy site. However, the 
panel of experts considered this option as of minor importance and 
the item was removed after 2nd round because of the low level of 
confidence expressed in the responses (median:4; IQR: 2– 7).
Besides, pre- treatment diagnosis has usually been based upon 
the information obtained from incisional biopsies although the na-
ture of AC as a non- homogeneous, multifocal lesion9 is a well- known 
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limitation for this approach. This can result in the underdiagnosis of 
dysplastic lesions and masking of non- contiguous foci of squamous 
cell carcinoma, even in diffuse and poorly demarcated lesions.9,38 
The chances for this to occur seem to be supported by the fre-
quently reported carcinomas in vermilionectomy surgical specimens 
(excisional biopsies) from patients with clinical diagnosis of AC40,41 
even in those cases with a previous incisional biopsy confirming no 
invasion.9
4.4  |  Therapeutic approaches
Different reports acknowledge a lack of consensus15- 18 and insuf-
ficient evidence for recommending a particular treatment option.18 
This circumstance reflects the absence of both controlled clinical 
trials and methodological standardization of AC studies.15- 18 This 
heterogeneity is favoured by the unclear clinico- histopathological 
definition of AC. Several studies have defined their AC cases before 
treatment relying only on clinical criteria,42- 44 and even on restric-
tive clinical criteria: ‘refractory cases’, ‘only severe diffuse damages 
cases’ or ‘non- ulcerated AC’.45 Conversely, certain reports defined 
AC according to Kaugar's criteria, which requires the presence of 
epithelial dysplasia.46- 49
Notwithstanding, five different systematic reviews have proved 
the superiority of surgical treatments over of non- surgical options in 
terms of histopathological control,15- 18,50 particularly partial surgery 
and laser therapy (CO2, Er- Yag, Thulium) alone or in combination 
with photodynamic therapy elicited the best clinical response,18 fol-
lowed by 5% imiquimod— topical chemotherapy drug— (once a day, 3 
to 5 days per week for 4 to 6 weeks) and photodynamic therapy.17,18 
However, topical and photodynamic therapy is associated with a 
higher recurrence.50 In any case, other non- surgical measures such 
as regular follow- up after treatment and intense photoprotection 
should also be implemented especially for high- risk patients.15,16,41
4.5  |  Implications for clinical practice and research
The choice of therapy should be based upon the clinical and histo-
pathological features of the lesion. Thus, mild- or non- dysplastic lesions 
can benefit from non- surgical approaches15,19 and surgical treatments 
should be prioritized for those cases with severe epithelial dysplasia, 
particularly vermilionectomy with serial analysis of the vermillion which 
could be the best option for diffuse and severe dysplastic lesions.
New strategies should be implemented to reach a consensus for 
the non- consensual statements identified in the current study, es-
pecially about the definition of a case and on the significance of ep-
ithelial dysplasia as a diagnostic criterion. More randomized clinical 
trials incorporating pre- treatment histopathological information and 
considering among their outcomes variables such as the remission 
rate, clinical response, changes to dysplasia grade, adverse events, 
cosmetic outcomes, healing time and recurrence rate, as well as 
follow- up, or malignization rate after treatment are needed to ease 
evidence- based decision- making. In addition, multicentric, longitudi-
nal (prospective cohort design) studies are required to identify bio-
markers able to predict malignant transformation in AC.35
5  |  CONCLUSIONS
AC is a potentially malignant disorder with a significant lack of agree-
ment on diagnostic criteria and procedures, biopsy indications and on 
the importance of ancillary techniques to assist in biopsy. However, and 
despite the insufficient evidence, a consensus was reached on the no-
menclature and the therapeutical management of this disorder, which 
can be useful to the clinicians in their decision- making processes.
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